News

FDA Statement on CCSVI
08/20/2012

The U.S. Food and Drug Administration (FDA) has released a statement regarding Chronic Cerebrospinal Venous Insufficiency (CCSVI) Treatment for Multiple Sclerosis also known as the "Liberation Procedure."  For patients who have expressed interest in CCSVI, please read their statement in the link below.  Your physicians at the IMSMP support the recommendations stated by the FDA.http://www.fda.gov/MedicalDevices...

more

Cocktails for a Cure 2012 - Friday, April 27
02/16/2012

THANK YOU to all who attended the 2012 Cocktails for a Cure.  This year's event was our most successful yet with over 500 tickets sold and more than $25,000.00 raised for research at the Multiple Sclerosis Research Center of New York!  Our deepest gratitude to Dana Schwartz and Ryan Cohen (pictured below).  This dynamic duo donates their time and collaborates on this event year after year!

 

Support MSRCNY and join us for Cocktails for a Cure 2012 where cocktails will flow...

more

Stem Cell Trial Update
02/15/2012

Since the November 2011 announcement, there has been tremendous interest in the IRB approved stem cell trial for multiple sclerosis. Due to the overwhelming response, the IMSMP and MSRCNY hope to expand the study to include 40 participants instead of the initially approved 20. The first six participants have already been selected, but therapy will not be initiated until funding through grants and private donors has been obtained. There are certain inclusion and exclusion criteria that must...

more

Grand Rounds - January 11th, 2012
01/11/2012

Dr. Sylvie Destian spoke at this morning's Grand Rounds on the topic of 'Imaging of Multiple Sclerosis'. She is a neuroradiologist at SUNY Syracuse and will be associated with the new MRI facility on the 3rd floor. This talk focused primarily on specialized imaging techniques for the clinical evaluation of Multiple Sclerosis as well as techniques for MS research. She also discussed the various disorders which can appear similar to MS on MRI.

'Like' us on Facebook!!
01/04/2012

Please check out the center’s new Facebook page!  Click “LIKE” on the IMSMP’s site page www.facebook.com/IMSMP and help support the battle against Multiple Sclerosis. You can also help spread the news of our page to friends and family by updating your status with a direct link to the page for others to see.

Grand Rounds
12/20/2011

Dr. Ralph Benedict, Professor of Neurology, Psychiatry and Psychology at the University of Buffalo, spoke at Grand Rounds last week. The title of his talk was "Neuropsychological Impairment in MS: Brain MRI Metrics, Cognition and Personality Change". The talk was very informative and the discussion focused on ways to correlate cognitive dysfunction with a variety of MRI parameters.

Planned 3rd Floor Expansion
12/01/2011

Our third floor expansion plans are well under way!! We hope to have the MRI facility up and running after the New Year. For a preview, click on the link below, which leads to renditions provided by our architectural firm, Yoshihara McKee, who were also our original architects for the Center.

http://www.yoshiharamckee.com/PROJECTS/institutional/imsmp2.html

Stem Cell Trial Approved!
11/21/2011

MSRCNY RECEIVES APPROVAL FOR GROUNDBREAKING
STEM CELL TRIAL IN MULTIPLE SCLEROSIS

Landmark Study Targets Repair and Regeneration for MS Patients

New York, NY- November 21, 2011- The Multiple Sclerosis Research Center of New York (MSRCNY) and the International Cellular Medicine Society (ICMS) jointly announced today the ICMS Institutional Review Board’s (IRB) approval of the first study to use autologous brain-like or neural stem cells for multiple sclerosis.

“We...

more

Ocrelizumab Phase II Trial Results
11/11/2011

The results of a small trial of a new medication called Ocrelizumab were recently published in the journal, The Lancet. Ocrelizumab is essentially the same as the currently available medication, Rituximab (although not FDA-approved for MS). Because of how it is made, however, Ocrelizumab may be better tolerated during the intravenous infusion. The effectivenss seems promising in this small study but there have also been significant safety concerns with this medication, including a death....

more

Symposium Question - “Why are there no approved medications for PPMS?”
11/10/2011

Unfortunately, there are a number of reasons that make progressive disease difficult to clinically study in a rigorous manner: 1. For one, there are poor animal models of progressive disease, which makes doing basic laboratory research challenging. Dr. Mueller in our lab is working on such an animal model. 2. It’s also very difficult to measure the worsening in progressive disease because there are no biomarkers for progression and our outcome measures are not very good. The outcomes in...

more

Pages

IMSMP

Because you deserve only the best in MS healthcare. Experience the difference.

521 West 57th Street

4th Floor

New York, NY 10019

p: 212.265.8070

f: 212.265.8194

Privacy Policy

        

Newsletter Sign Up

Join our mailing list today!  Receive the latest information and updates happening in MS research, treatment and care including, Healing MS, the IMSMP newsletter.

* We don’t share your information with anyone.